Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials
Authors' conclusion
These results support a relationship between semaglutide 2.4 mg treatment of overweight and obesity and reduced need for antihypertensive and lipid-lowering treatment, facilitating treatment intensity reduction/discontinuation and abating treatment intensification.
Study context
- Population
- People with overweight or obesity (STEP 1, 3, 6, 8 pooled) and, separately, with overweight or obesity and T2D (STEP 2 and 6 pooled)5 STEP trials
- Comparison
- Semaglutide 2.4 mg vs placebo
- Outcome
- Changes in antihypertensive or lipid-lowering treatment intensity
- Follow-up
- Randomization to end of treatment
Methodological detailsplacebo-controlled
- Placebo-controlled
Pooled result
As reported in the abstract
Antihypertensive or lipid-lowering treatment intensity changes · end of treatment
- In both pooled samples, a higher proportion with semaglutide 2.4 mg vs placebo had antihypertensive or lipid-lowering treatment intensity reduction
- In both pooled samples, a smaller proportion with semaglutide 2.4 mg vs placebo had antihypertensive or lipid-lowering treatment intensification
- Post hoc analysis
Further pooled results
Body weight in participants receiving antihypertensive or lipid-lowering medications
- Greater numeric reductions in body weight with semaglutide 2.4 mg vs placebo in both samples
Original publication
Effect of semaglutide 2.4 mg on use of antihypertensive and lipid‐lowering treatment in five randomized controlled STEP trials. Obesity (Silver Spring). Published 5 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →